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Background: Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma and infects
about 3% world population. Response to interferon therapy depends upon the genotype of the virus and factors
associated with the host. Despite a good response to interferon therapy, a considerable number of genotype 3a
infected patients remains unalleviated.
Results: In total forty-nine patients including twenty-five non-responders (non-SVR) and twenty-four responders
(SVR) were recruited. Patients were tested for viral status at different intervals and the isolated RNA was sequenced
for the NS5A region in both groups. The comparison of PKRBD of HCV between the SVR and non-SVR patients did
not confirm any significant difference in the number of mutations. However, when the sequence downstream to
the PKRBD of NS5A was compared, two important statistically significant mutations were observed; at positions 2309
(Ala to Ser) and 2326 (Gly to Ala). These mutations were then analysed for tertiary protein structure and important
structural changes were observed. Statistically significant difference was also observed when age groups of patients
were compared; younger patients showed better response than the older ones.
Conclusions: The region between PKRBD and IRRDR may be important for prediction of response to IFN therapy for
genotype 3a. ISDR and PKRBD have not shown any involvement in treatment response. Further functional analyses
of these findings can help in understanding the involvement of the NS5A region in interferon treatment of HCV-3a
infected patients.Background
Hepatitis C is a major health problem infecting about
180 million people worldwide and is a leading cause of
chronic liver disease and hepatocellular carcinoma [1].
Prevalence of HCV is highest in Egypt, about 22%
followed by Pakistan with 4.7% infected individuals.
This high carrier rate of infected individuals is due to
many reasons including the injudicious use of injections,
reuse of syringes and needles, and through shaving
tools [2-4].
Interferon-alpha along with ribavirin is commonly used
to treat the infected patients. Response to treatment varies
from person to person and is also dependent on the viral* Correspondence: atikamansoor@hotmail.com
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reproduction in any medium, provided the orgenotype. HCV genotype appears to be the main predictor
of treatment outcome; genotypes 2 and 3 show better
response than genotype 1. In Pakistan genotype 3 is the
most common type and shows 70-80% response to
interferon therapy [5,6]. In spite of a better response
compared to other genotypes, a considerable number
of individuals remains unrelieved.
Various viral and host factors play a major role in
response to interferon therapy; Human leukocyte antigen
(HLA) and interleukin 28B (IL28B) being the most
commonly studied host factors [7], whereas the viral
factors that are frequently studied to predict response to
interferon therapy include sequence variability in envelope
protein E2, V3 and NS5A regions. Protein kinase R
binding domain (PKRBD) of NS5A is a 63 amino acid
sequence in which interferon sensitivity determining
region (ISDR) is comprised of first 40 amino acids. Thisal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with protein kinase R (PKR) that inhibits dimerization
of PKR and stops its antiviral activity [8-11].
ISDR of the NS5A gene has shown association with
non-response in Japanese genotype 1 positive patients
[11]. In these patients, the presence of wild type ISDR
sequence that is a prototype HCV strain (HCV-J) is an
indication of non-response to treatment. However, if
there are more than four mutations in the wild type
ISDR sequence, there is a better chance of sustained
virological response [11]. Few studies carried out to
analyse changes in ISDR of HCV-3a showing SVR have
presented variable results regarding the involvement of
this region in HCV replication and clearance [12-16].
In Pakistan about 10 million individuals are reported
to be infected with HCV and the data available on various
viral genome factors is not sufficient to determine the
response to interferon therapy [2,8]. The present study
was planned to investigate the role of PKRBD diversity
in response to interferon therapy. In addition, the 3′
sequence outside the PKRBD of NS5A was also analysed
to compare the SVR and non-SVR patients infected
with 3a genotype.Results
Patients’ response to treatment
Among patients the male and female representation was
equal as shown in Table 1. Mean age of non-SVR group
was 51 years (range 34–63 years), higher than the SVR
group (mean age 43 years, range 21–62). The two groups
were compared and statistically significant difference was
observed in ages on HCV clearance (p = 0. 003). However,
there was no difference in ALT levels (p = 0. 66) at the
start of treatment on HCV clearance. Statistically sig-
nificant differences between SVR and non-SVR patients
were also observed in the viral load and rapid virological
response (RVR; Table 1). Patients with low viral load
and with RVR showed a better response to therapy
compared to those with high viral load and no RVR group.
Viral loads of both patient groups were compared with




Males 11 (44%) 11 (46%) ns
Females 14 (56%) 13 (54%) ns
Age Mean (range) 51 (34–63) 43 (21–62) p =0.003
ALTs Mean (range) 119 (45–653) 104 (19–728) ns
RVR Achieved (%) 22 (92%) 6 (24%) p < 0.0001
Viral load Range 50000-3300000 3300-2000000 p = 0.038
ns, not significant.downstream region but no association was found in any of
the comparisons.
Treatment outcome in relation to PKRBD sequence
A 416 bp fragment of the NS5A region covering ISDR
and PKRBD was sequenced to find out differences in the
number of mutations in SVR and non-SVR patients. These
sequences were further divided into different regions;
PKRBD, ISDR and region outside PKRBD. Amino acid
sequences of the PRKBD were aligned and compared
with the already published sequences of the genotype
3a from different regions including India, Brazil, New
Zealand and Australia (Additional file 1: Table S1). The
sequence identity matrix did not show any significant
differences in the amino acid sequence; however, few
hyper variable regions were detected in different strains
(Additional file 1: Figure S1). The New Zealand strain
(NZL1) was almost identical to the already published
Pakistani strain (pk1). The NZL1 (GenBank D17763)
strain was used for further comparisons and analyses. Few
of the mutations specific to Pakistani HCV population are
shown in Figure 1. The number of mutations in PKRBD
varied from 0–8 in SVR patients (average = 4) and from
0–9 (average = 3.8) in non-SVR patients. There was no
statistically significant difference in the number of mu-
tations between SVR and non-SVR patients in ISDR
and PKRBD (Figure 1). However, when the sequence
outside the PKRBD (2281–2335) was analysed, differences
were observed between the two groups at some amino
acid positions (Figure 2). There was Ala at position 2309
in the reference strain, whereas a substitution mutation at
this point led to a Ser in most of the samples. When this
mutation was compared between the SVR and non-SVR
patients, significant difference at this point (p = 0.03) was
observed. Similarly, at position 2326 Gly was present in
reference strain which was replaced by Asn and Ala in
many samples. The presence of Ala showed significant
association with clearance of hepatitis C virus (p = 0.03).
Both of these mutations were higher in SVR samples
showing some association with viral clearance in response
to interferon therapy.
Tertiary structure analysis
NS5A structural changes were studied by using mutations
present in our samples that showed statistically significant
association (Figure 3). The A2309S substitution was in
a highly conserved region, located within a stretch of
residues annotated in Uniprot as a special region: “Tran-
scriptional activation; NS4B-binding”. The mutant residue
was bigger and was less hydrophobic than the wild
type which might lead to bumps and changes in
hydrophobicity. It can also lead to loss of hydrophobic
interactions, either in the core or surface of the protein.
Similarly, substitution G2326A also generated a bigger
Figure 1 Sequence alignment of PKRBD sites including ISDR domain. The SVR and non-SVR are shown as ‘R’ and ‘NR’ in their ID as suffix,
respectively. Although there are various mutations in the samples but no statistically significant difference in the number of mutations between
SVR and non-SVR patients in ISDR and PKRBD was observed.
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a stretch of residues annotated in Uniprot as a special
region: “Transcriptional activation”. The Gly residue is the
most flexible residue and it is possible that this residue
is needed at this position to make a special backbone
conformation or to facilitate movement of the protein.
The mutation introduces a less flexible residue thereby
disturbing this conformation or movement of the protein.
RMSD value of 0.004 Å was observed for A2309S and
0.002 Å for G2326A. Generally RMSD value between 0
and 1.5 Å represent very similar structures while the
increase in RMSD means increased structural dissimilarity.
Moreover, small RMSD computed over large structures
were also very significant as compared to larger RMSD
values computed over structures with a small numberof residues. NS5A is a medium sized protein so the
observed RMSD values of 0.004 Å and 0.002 Å means
non-significant structural variations. The biochemical
differences, nature and location of amino acid substitution
can affect the protein in various ways and is therefore
important to determine whether it can alter the protein
function. Theoretical pI of the native NS5A protein
was observed as 5.40, which remained unaltered in the
mutants, while differences were observed in the alphabetic
index and GRAVY. The native protein has an alphabetic
index of 66.26 while its GRAVY was −0.418, which were
observed deviated in the mutants as 66.04 and −0.424 for
A2309S and 66.48 and −0.413 for G2326A, respectively.
The alternations of key residues in a protein cause loss of
its normal biological functions. It was observed that both
Figure 2 Comparison of NS5A sequence outside the PKR binding site. When the NS5A sequence outside the PKRBD (2281–2335) was
analyzed, we found the differences between the SVR and non-SVR groups at some amino acid positions. At position 2309 aa Ala to Serine and at
position 2326 aa Gly to Ala changes showed statistically significant difference in SVR and non-SVR patients (p ≤ 0.05). Student’s t-test was used for
statistical analysis.
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to be TOLERATED with a score of 0.51 and 0.22 by
SIFT while regarded as benign by PolyPhen with scores
of 0.000 (sensitivity: 1.00 and specificity: 0.00) and 0.001
(sensitivity: 0.99 and specificity: 0.15).
Discussion
HCV is a major public health problem these days in many
countries with global distribution. Generally patients
infected with HCV genotype 3a show good response to
interferon treatment and the number of non-SVR in
HCV 3a patients are quite low; less than 30 percent
[5,6]. In order to investigate the non-response of these
patients towards interferon therapy, a study was designedin which 25 non-SVR patients with genotype 3a and
approximately an equal number of randomly selected
SVR patients with the same genotype were included.
Statistically significant differences in the age groups
were found when these patients were compared with
each other. Response to IFN therapy was greater in
younger patients compared to the older ones, as
reported previously also [17-19]. It is well known that
marked changes in immune response occur with increasing
age resulting in blunt immune response. Initial viral load
and RVR have been used to predict patients’ final outcome
of IFN therapy in many studies and a correlation was
also observed in our sample pool [20,21]. Patients with
low viral load at the start of the treatment had a greater
Figure 3 NS5A structure changes were studied by using mutations present in our samples. Two of the mutations 2309 (Ala to Ser) and
2326 (Gly to Ala) are present in the transcriptional activation domain. (A) Partial structure of NS5A with native residue Ala at position 331 (position 2309
of the poly-protein). (B) The first mutation at location 2309 (Ala to Ser) changes the backbone of the amino acid due to the presence of a OH group in
the side chain of the new amino acid. The native residue (Ala) is non-polar and more hydrophobic than the mutant, which is a polar one. (C) Partial
structure of NS5A with native residue Gly at position 348 (position 2326 of the poly-protein). (D) Mutation at location 2326 (Gly to Ala). The mutant
residue is bigger than the native Glycine. The native residue is the most flexible residue and it is possible that this residue is needed at this position to
make a special backbone conformation or to facilitate movement of the protein.
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therapy. Among all the factors analysed RVR was the
strongest factor positively associated with viral clearance.
Various studies have been carried out in order to
observe the role of ISDR, PKRBD and other sequences
present outside the PKRBD of NS5A in response to IFN
therapy. Most of these studies have shown association of
the number of mutations in these regions to IFN therapy
response, especially in the Japanese population and in
some European populations as well [11,22-25]. The main
aim of the present study was to investigate PKRBD of
NS5A sequence that has always been a region of interest
due to its involvement in interferon resistance. NS5A
is about 447 amino acid long sequence that plays an
important role in replication and is divided into three
domains separated by two low complexity sequences
(LCSI & II; [26]). ISDR and PKR binding site exist
between LCSI and domain II [9-11]. ISDR has beenpreviously reported to be involved in treatment response
in patients infected with genotype 1 [10]. ElHefnawi et al.
[27], reported variations in ISDR that were clustered in
the SVR groups and some of the positions were associated
with viral clearance. One such position significantly
associated with subtypes, 1a and 1b was 2228 [27]. When
the SVR and non-SVR groups in our sample pool were
compared, no difference in the number of mutations in
the ISDR region was observed. Other studies on 3a
genotype have also shown little or no changes in amino
acid sequences when compared with the reference strain
(NZL1). Results presented in this study are consistent with
previous findings on treatment response of HCV patients
to interferon in relation to ISDR sequence variation
[12-14]. These results indicate that at least for genotype
3a, ISDR might not be a predictor of SVR in HCV infected
patients. PKRBD of NS5A when activated inhibits trans-
lation of messenger RNA. Presence of mutations in this
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PKR and NS5A. In the present study, the number of
mutations in the PKRBD was also not statistically
significant suggesting that in our pool PKRBD may
not be affected by the number or types of mutations
present. Our results are in agreement with other studies
showing non-involvement of PKRBD in interferon therapy
response [12-14].
We further extended our region of analysis outside the
PKRBD and interesting results were found at two positions,
which showed statistically significant results. These were
substitution mutations, Ala to Ser at position 2309 and
Gly to Ala at position 2326. Both of the mutations
showed association with viral clearance in SVR patients.
Association of mutations outside PKR with treatment
outcome have also been reported by Zhou et al., [28]
particularly in genotype 1b. El-Shamy et al. [29], have
identified a region downstream to ISDR named as IFN/
Ribavirin resistance determining region (IRRDR) in
genotype 1b. They have further shown variability in this
region in genotypes 2a and 2b. IRRDR is extremely
variable in most of the HCV genotypes with highly
conserved upstream and downstream sequences. The
heterogeneity in this region is associated with better
treatment response. We have also observed that the
mutations identified in the present study are correlated
with viral clearance following IFN/RBV treatment regimen
(Figure 2), although these mutations are present upstream
of the IRRDR region. Therefore, we suggest that the region
upstream to IRRDR may also be important in relation to
viral clearance with IFN/RBV at least for genotype 3a.
The mutations identified in the sequence were further
analysed for their effect on the structure of the protein.
Both mutations seemed to affect protein properties.
Residue substitutions due to missense mutations can
affect the protein high order structure which determines
protein functions. HCV NS5A structural variations were
therefore analysed by using missense mutations present
in our samples that showed statistically significant asso-
ciation (Figure 3). On the basis of these results we can
only predict that the presence of these mutations is
somehow affecting the interferon effect in HCV infected
patients. These mutations are probably giving selective
protection to the patients who in turn show better
response towards interferon therapy. On the other hand
absence of these mutations in NS5A leads to non-response.
Besides the viral factors, host factors including HLA
alleles and interleukins (especially IL28B) can also be
helpful in predicting the IFN therapy outcome. Poly-
morphisms in and around IL28B gene have shown an
association to IFN therapy; rs12979860 being most
widely studied [30-32]. However, no data are available
for polymorphisms in IL28B from Pakistan so far.
Therefore, study of these polymorphisms will be helpfulin predicting the treatment response in HCV patients and
these viral and host factors together can help in deciding
the treatment regimen for the patients of this region.
Conclusion
In conclusion, we can say that ISDR and PKRBD of
HCV-3a genotype are not predictive markers for the out-
come of interferon therapy. However, the downstream
region to the PKRBD of NS5A might be playing some
role in this regard. The mutations in the downstream
region of NS5A presented here and their relation to
interferon therapy are reported for the first time. Further
studies are needed to confirm these results and an in vitro
cellular model system is needed to verify the effect of these
mutations.
Methods
Subjects and response classification
A total of 49 HCV patients infected with HCV (3a)
genotype were included in this study. Blood samples of
the patients were collected after the patients gave their
written informed consent. This study was approved by
the Institute of Biomedical and Genetic Engineering
Ethical Committee and was in compliance with the
Helsinki Declaration. All patients included in the study
were treatment naïve and were HCV 3agenotypepositive.
In Pakistan it is a routine practice in most of the hospitals
to give standard interferon therapy that includes three
million unit standard IFN three times a week with
600 mg ribavirin twice a day for at least six months (72
injections). All of the patients were tested for HCV
RNA at the start of the treatment, after four weeks for
a rapid virological response (RVR) and then at the end
of therapy for end of treatment response (ETR). At the
end of treatment the patients who did not clear the
virus were treated as non-sustained virological response
(non-SVR). Whereas, the patients who responded to
the therapy were monitored for sustained virological
response (SVR) six months after the end of treatment
and were grouped as responders. Samples for the study
were collected during the year 2008 to 2011 and the
viral load of the patients was determined by Qiagen kit
(Artus HCV RG RT-PCR kit). The exact route of viral
infection is not clear; however, most of the patients had
the history of dental treatment or surgery. Basic clinical
parameters of the patients are given in Table 1.
HCV detection and genotyping
Plasma/serum from HCV infected patients were separated
within 1 hour of blood collection and stored at −20°C.
HCV RNA was isolated using a commercially available
QIAamp Viral RNA Mini Kit (Qiagen Cat. # 52906) and
detected by Qiagen kit (Artus HCV RG RT-PCR kit).
HCV genotyping was performed as described previously
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4, 5a and 6.
Primer designing for NS5A
D17763 NZL sequence of HCV-3a was used as a reference.
NS5A sequence including ISDR region was retrieved from
NCBI database and primers were designed using primer
3 software available online [34]. Primers selected for
amplification of about 416 bp were as follows: forward
primer (5′ CGCGGGTCMCCTCCATCAGA 3′) and
reverse primer (5′ TTCCTCCGRGGGGAGGCAC 3′).
These primers were synthesized from MWG operon
(Biotech, UK).
PCR amplification of NS5A region and sequencing
Purified RNA samples were subjected to reverse tran-
scription and amplification by using a OneStep RT PCR
kit from Qiagen (Cat #210212). Briefly RNA samples were
reverse transcribed at 50°C for 30 minutes, denatured
at 95°C for 15 minutes and amplified for 40 cycles, each
consisting of denaturation at 94°C, annealing at 60°C
and extension at 72°C for 1 minute each. Amplified
products were confirmed on 2% agarose gel and were
then sequenced bidirectionally using standard protocols.
Sequenced products were separated on 3130 Genetic
Analyzer (ABI part no. 4363785), data were collected and
analysed by ABI genetic analysis software. The sequences
obtained were compared manually to the reference
sequence D17763 NZL.
Statistical analysis
Amino acid sequences of samples were aligned by Mo-
lecular Evolutionary Genetics Analysis software (MEGA
version 5 [35]) and aligned sequences were exported to
Microsoft excel for calculation of number of mutations
and their averages. For comparison between responders
and non-responder groups, Fisher exact test was applied
using VassarStats (http://faculty.vassar.edu/lowry/tabs.html)
and P ≤ 0. 05 was considered as statistically significant.
Two tailed Student’s t-test was used to assess differences
in age groups and ALT levels.
Sequence and structural analysis
Sequence of HCV NS5A protein with accession number
D17763 was retrieved from UniProt (www.uniprot.org)
database for detailed structure based assessment. For a
detail insight, three dimensional structure of HCV NS5A
protein was predicted through I-TASSER server [36], refined
through ModRefiner [37] for quality enhancement and
validated for quality assurance through WHATIF [38].
The observed mutations, A2309S and G2326A were
substituted in the native sequence of HCV NS5A using
MUTATE_MODEL [39] to get the mutant versions for
investigating structural and functional deviations. Themutant models were compared against the native in 3D
through PDBeFOLD (http://www.ebi.ac.uk/msd-srv/ssm)
for structural similarities. Physiochemical properties were
predicted through ProtParam (http://au.expasy.org/tools/
protparam.html). Sorting intolerant from tolerant amino
acid substitutions based on sequence homology was
predicted through SIFT [40] to predict whether an amino
acid substitution in a protein will have a phenotypic effect.
The damaging substitutions were further sorted from the
benign by using PolyPhen server (genetics.bwh.harvard.
edu/pph/), which predicts the possible impact of residue
substitution on the structure and function of a human
protein.
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imedia/1948169713111749/supp1.doc.
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